AstraZeneca PLC - American Depositary Shares (NY:AZN)

189.90 -2.60 (-1.35%)

Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Volume	1,429,048
Open	192.64
Bid (Size)	187.71 (100)
Ask (Size)	195.00 (300)
Prev. Close	192.50
Today's Range	189.43 - 193.65
52wk Range	183.63 - 212.71
Shares Outstanding	N/A
Dividend Yield	0.49%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis

Today 10:14 EDT

In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new...

Via MarketMinute

The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026

March 11, 2026

The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining...

Via MarketMinute

Performance

YTD	+0.8%	+0.8%
1 Month	-7.3%	-7.3%
3 Month	+0.8%	+0.8%
6 Month	+0.8%	+0.8%
1 Year	+0.8%	+0.8%

More News

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

Via Finterra

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 09, 2026

From AstraZeneca

Via Business Wire

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

Via MarketMinute

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Via The Motley Fool

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Via MarketBeat

After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗

February 27, 2026

Via MarketBeat

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange

February 26, 2026

Via MarketMinute

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20, 2026

From AstraZeneca

Via Business Wire

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

February 16, 2026

Via The Motley Fool

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

Via MarketMinute

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

February 13, 2026

From AstraZeneca

Via Business Wire

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗

February 12, 2026

Via MarketBeat

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges

February 11, 2026

Via MarketMinute

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

February 11, 2026

From AstraZeneca

Via Business Wire

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

Via MarketMinute

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

February 10, 2026

Via Finterra

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?

Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.

What exchange does AstraZeneca PLC - American Depositary Shares trade on?

AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?

The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange

What is the current price of AstraZeneca PLC - American Depositary Shares?

The current price of AstraZeneca PLC - American Depositary Shares is 189.90

When was AstraZeneca PLC - American Depositary Shares last traded?

The last trade of AstraZeneca PLC - American Depositary Shares was at 03/13/26 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.